Zykadia (ceritinib; Novartis) is a tyrosine kinase inhibitor that targets anaplastic lymphoma kinase (ALK). In most ALK-positive non-small cell lung cancer (NSCLC) cases, inversions in chromosome 2 cause ALK to fuse to echinoderm microtubule-associated protein-like 4. This activates the ALK kinase domain and downstream signaling pathways responsible for excess cancer cell proliferation. ALK gene rearrangements are found more commonly in younger, non-smoking NSCLC patients and make up 3–5% of all NSCLC cases.
4 Drug Overview
5 Product Profiles
5 Zykadia : Non-small cell lung cancer (NSCLC)
LIST OF FIGURES
11 Figure 1: Datamonitor Healthcare’s drug assessment summary for Zykadia in non-small cell lung cancer
12 Figure 101: Datamonitor Healthcare’s drug assessment summary for ensartinib in non-small cell lung cancer
14 Figure 102: Datamonitor Healthcare’s drug assessment summary for ensartinib in non-small cell lung cancer
LIST OF TABLES
5 Table 1: Zykadia drug profile
7 Table 2: Zykadia pivotal trial data in non-small cell lung cancer
15 Table 3: Zykadia sales for NSCLC across the US, Japan, and five major EU markets, by country ($m), 2017–26
17 Table 4: Zykadia patient numbers for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.